

Antimicrobial Activity of Aztreonam -avibactam and Comparator Agents against Ceftazidime -

Objective

To evaluate aztreonam-avibactam activity against a global (ex-USA) collection of contemporary ceftazidime-avibactam-resistant (CAZ-AVI-R) Enterobacterales

Methods

- ‡ 20,750 unique isolates were consecutively collected in 2019-2021.
- ‡ Among these isolates, 285 (1.4%) were CAZ-AVI-R and were isolated from 38 medical centres in 24 countries.
- ‡ Isolates were tested by reference broth microdilution (CLSI).
- ‡ Aztreonam-avibactam was tested with avibactam at fixed 4 mg/L.
- ‡ EUCAST interpretive criteria were applied to comparators.
- ‡ CAZ-AVI-R isolates collected in 2019-2020 (n = 232) were submitted to whole genome sequencing (WGS).

Results

Table 1. Antimicrobial susceptibility of 285 CAZ-AVI-R Enterobacterales

Results

An MBL gene was identified in 214 of 232 (92.2%) isolates submitted to WGS

Results

Acknowledgements

Contact